Feb 11 (Reuters) - Abbvie ( ABBV ) sued the U.S.
Department of Health and Human Services on Wednesday,
challenging a decision by the Centers for Medicare & Medicaid
Services to select Botox for prescription drug price controls
established by the federal Inflation Reduction Act of 2022.
The lawsuit was filed in the Washington, D.C. federal
court. It also names CMS and its administrator Mehmet Oz as
defendants.
(Reporting by Jonathan Stempel in New York)